Elanco Animal Health Inc Earnings Per Share Disclosure
| 2025 | 2024 | 2023 | ||||||||||||||||||
| Basic weighted-average common shares outstanding | 496.4 | 494.0 | 492.3 | |||||||||||||||||
Assumed conversion of dilutive common stock equivalents (1) | — | 3.3 | — | |||||||||||||||||
| Diluted weighted-average shares outstanding | 496.4 | 497.3 | 492.3 | |||||||||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 24, 2026 | Showing above |
| 2024 | Feb 25, 2025 | |
| 2023 | Feb 26, 2024 | |
| 2019 | Feb 28, 2020 | |
| 2018 | Feb 20, 2019 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.